Abstract: A drillstring, in a drilling environment, operatively connected to an information handling system, where the information handling system is configured to perform a method for modifying drilling operations that includes obtaining measured drillstring data associated with the drillstring, and calculating a heat generation using the measured drillstring data, where, based on the heat generation, a drilling modification procedure is performed.

Abstract: Various embodiments of freeze dryers and drying processes are disclosed that can be used to dry materials with low water content (no more than 20 wt % water) and/or high sugar content (at least 20 wt % sugar). Such materials include candy, confections, and the like. In one embodiment, a drying process includes drying the materials without freezing them. In another embodiment, a drying process includes warming the materials before drying them. In another embodiment, a drying process includes drying two batches of materials with low water content sequentially without defrosting the interior of freeze dryer.

Abstract: Various embodiments of freeze dryers and drying processes are disclosed that can be used to dry materials with low water content (no more than 20 wt % water) and/or high sugar content (at least 20 wt % sugar). Such materials include candy, confections, and the like. In one embodiment, a drying process includes drying the materials without freezing them. In another embodiment, a drying process includes warming the materials before drying them. In another embodiment, a drying process includes drying two batches of materials with low water content sequentially without defrosting the interior of freeze dryer.

Abstract: Various embodiments of freeze dryers and drying processes are disclosed that can be used to dry materials with low water content (no more than 20 wt % water) and/or high sugar content (at least 20 wt % sugar). Such materials include candy, confections, and the like. In one embodiment, a drying process includes drying the materials without freezing them. In another embodiment, a drying process includes warming the materials before drying them. In another embodiment, a drying process includes drying two batches of materials with low water content sequentially without defrosting the interior of freeze dryer.

Abstract: The present disclosure provides compounds according to Formula I or a pharmaceutically acceptable salt thereof: wherein each variable is as defined and described herein, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

Abstract: The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.

Abstract: A light assembly for a scooter includes a first and a second bar mount component having a first and a second through hole respectively. The first or second through hole of the first or second bar mount component is slidably inserted on to a kiddy bar secured to a front portion of the scooter. The light assembly includes a center component having an elongated portion, each end of the elongated portion being attachable to an inner surface of the first or second bar mount components. The light assembly includes a headlight support piece attachable to the center component and the headlight support piece to support a weight of a front headlight of the scooter, and a metal rod extends through a third through hole of the center component and a fourth through hole at the front headlight to prevent the front headlight from detaching from the center component.

Abstract: The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

Abstract: The present disclosure relates generally to Cyclin-dependent kinase 2 (CDK2) inhibiting chemical compounds and uses thereof in the inhibition of the activity of CDK2. The disclosure also provides pharmaceutically acceptable compositions comprising compounds disclosed herein and methods of using said compounds and compositions in the treatment of various disorders related to CDK2 activity.

Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: The present disclosure provides compounds, compositions thereof, and methods of using the same for the inhibition of CDK2, and the treatment of CDK2 related diseases and disorders.

Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: A freeze drying method including vacuuming freezing food, confirming operational status of at least one of a pressure sensor, a temperature sensor, a heating system, a cooling system, and/or a vacuum pump, and/or performing at least one of pre-frozen or not frozen status check, a chamber pre-freezing process, a vacuum leak check, a drying process, a final dry process, including any of such processes described in the specification.

Abstract: A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

Abstract: A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.

Abstract: A combination comprising a BCL-2 inhibitor and a MCL1 inhibitor, and compositions and uses thereof.

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.